Recent aspects in the diagnosis and prognosis of bladder cancer.
Epidemiologic studies have stated the progressive increase of bladder tumors during the last decades. The aim of our review is to refer to factors implicated in bladder carcinogenesis (such as activated oncogenes, growth factors and chromosomal aberrations) and to resistance to drug uptake (i.e., multidrug resistance gene and P-glycoprotein). The review also provides information of diagnostic and prognostic significance, based on DNA analysis of transitional cancer cells. In addition to cytometric data, alternative counterings for estimation of the S-phase fraction, useful in indicating the biologic behavior of bladder cancer, are presented. Knowledge of such mechanisms results in a better approach to the diagnosis, prognosis and prevention of bladder carcinomas, especially those that do not respond to systemic intravesical chemotherapy. We have tried to mention all significant factors related to the development of bladder cancer. We conclude that the progress made in understanding the pathogenesis of bladder cancer has been significant. However, more studies are needed in order to introduce and adopt reliable criteria to accurately predict the clinical behavior.
Department of Pathology, G. Gennimatas General Hospital of Athens, Greece. gkonto@atlas.uoa.gr
G
G
Kontogeorgos
D
D
Aninos
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002869:Chromosome Aberrations / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D003937:Diagnosis, Differential; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011237:Predictive Value of Tests; D011379:Prognosis; D011519:Proto-Oncogenes / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004273:DNA, Neoplasm; D004815:Epidermal Growth Factor; D066246:ErbB Receptors